GLP-1 Peptides Explained: Semaglutide, Tirzepatide, Retatrutide & Liraglutide

For research and educational purposes only. This guide explains selected published studies and their limits. It does not give dosing advice or recommend a medicine or research compound. Clinical-trial findings concern the specific pharmaceutical formulations studied.

Liraglutide and semaglutide act at the GLP-1 receptor. Tirzepatide combines GIP and GLP-1 receptor activity, while retatrutide combines GIP, GLP-1, and glucagon receptor activity. Receptor coverage is a useful starting point; the number of targets does not by itself establish a better outcome or a safer compound. The original tirzepatide development study and retatrutide phase 2 trial describe the multi-receptor compounds they tested.

This guide compares selected evidence for the four compounds. It does not attempt to catalogue every trial or provide a current regulatory-status register. For more study-by-study context, use the linked compound profiles and the evidence guide.

The GLP-1 Receptor: Mechanism and Outcomes

GLP-1 is an incretin hormone. Its receptor is involved in glucose-dependent insulin secretion, appetite regulation, and gastrointestinal function. Long-acting agonists were developed to extend activity beyond that of the native hormone. A published review of GLP-1 receptor agonists provides background on these pathways and drug development; it is a review of the literature, not a new clinical experiment.

A receptor-level explanation and a clinical result answer different questions. Receptor assays can establish activity in a defined system. A clinical trial measures outcomes in its selected population, with its own formulation, follow-up period, comparators, and adverse-event monitoring. Neither type of evidence should be presented as answering every question about a compound.

Milestones in the Selected Published Evidence

The following dates identify the papers discussed here, rather than a complete history of the class:

• 2015: A placebo-controlled liraglutide trial reported weight outcomes over 56 weeks in adults without type 2 diabetes. Original trial.
• 2018: The tirzepatide development report linked receptor and mouse experiments with early human studies of LY3298176. Original development study.
• 2021: STEP 1 reported semaglutide versus placebo over 68 weeks in adults with overweight or obesity without diabetes. Original STEP 1 trial.
• 2023: A phase 2 retatrutide trial reported weight and adverse-event outcomes across several treatment groups over 48 weeks. Original phase 2 trial.

Later publication does not automatically mean stronger evidence. Trial phase, design, population, and comparator remain essential.

Liraglutide: A GLP-1 Receptor Agonist

The cited liraglutide trial randomized 3,731 adults without type 2 diabetes to liraglutide or placebo, alongside lifestyle counseling. Participants had obesity or overweight with specified related conditions. At 56 weeks, average weight loss was 8.4 kg in the liraglutide group and 2.8 kg in the placebo group. Nausea and diarrhea were the most frequently reported adverse events. Original randomized trial, NEJM, 2015.

These findings concern that study's selected population and regimen. They should not be compared directly with a percentage reported in a different trial as if the participants had been randomized between the two medicines.

Exposure Is a Separate Research Question

A population pharmacokinetic analysis of liraglutide found that body weight and sex influenced exposure in the datasets it studied. Original pharmacokinetic analysis, 2016. This illustrates why receptor identity alone does not define an exposure profile. It is not a basis for calculating an individual dose from this article.

Semaglutide: Reading STEP 1 in Context

STEP 1 randomized 1,961 adults with overweight or obesity without diabetes to semaglutide or placebo, with lifestyle intervention in both groups. At 68 weeks, average body-weight change was −14.9% with semaglutide versus −2.4% with placebo. Gastrointestinal events led to treatment discontinuation in 4.5% and 0.8% of the respective groups. Original STEP 1 trial, NEJM, 2021.

The comparator was placebo. STEP 1 did not compare semaglutide directly with liraglutide, tirzepatide, or retatrutide. It also does not establish that a research supplier's material is equivalent to the pharmaceutical formulation used in the trial.

For readers comparing GLP-1 agonists, the useful questions are which outcome was prespecified, how missing data and discontinuations were handled, and whether the study population matches the question being asked. A large result without that context is incomplete evidence.

Tirzepatide: Dual GIP and GLP-1 Receptor Activity

The original LY3298176 development report demonstrated activity at both GIP and GLP-1 receptors in assays, followed by mouse experiments and early randomized human studies. Across its human study groups, 142 participants received an investigational or comparator treatment. Repeated-administration studies lasted four weeks and primarily investigated safety and tolerability. The report described glucose and weight changes in some groups; gastrointestinal adverse effects were commonly reported. Original development study, Mol Metab, 2018.

This paper establishes early evidence for dual-receptor activity and clinical proof of concept. Its short duration cannot establish long-term comparative benefits or rare risks. Later clinical trials must be evaluated separately rather than treating this early report as a summary of the entire tirzepatide evidence base.

What Does an Extra Receptor Explain?

A comparison between tirzepatide and another molecule does not, on its own, isolate the contribution of GIP receptor activity. The molecules may also differ in exposure, receptor potency, formulation, and other properties. Attribution to one pathway requires a design that can distinguish those explanations. “Dual agonist” describes receptor activity; it is not a complete causal explanation for every clinical difference.

Retatrutide: Triple Agonism and a Phase 2 Trial

The cited phase 2 trial randomized 338 adults with obesity, or overweight plus a related condition, to retatrutide groups or placebo. At 48 weeks, mean weight change ranged from −8.7% to −24.2% across active groups, versus −2.1% with placebo. Gastrointestinal adverse events were common, and increases in heart rate were observed. Original phase 2 trial, NEJM, 2023.

This was not a direct comparison with semaglutide or tirzepatide. Its results cannot establish that retatrutide is superior to either, and its size and duration limit conclusions about uncommon adverse events or long-term outcomes.

Adding glucagon receptor activity also does not establish which portion of the observed outcome came from that receptor. The trial tested the combined molecule, not each receptor pathway independently.

Comparing the Four Compounds

This table summarizes the linked papers; it is not a ranking or a complete evidence assessment. Weight change in kilograms, percentage weight change, glycemic outcomes, and cardiovascular events are different endpoints. They should not be placed on a single scale without an appropriate analysis.

How to Make a Useful Comparison

For any claimed difference, check:

1. The population: diabetes status, starting characteristics, and enrollment criteria.
2. The comparison: placebo, another medicine, or a comparison assembled across separate studies.
3. The endpoint and time: what was measured, when, and whether it was prespecified.
4. The analysis: handling of missing observations, discontinuations, and uncertainty.
5. The material: the pharmaceutical formulation and protocol actually studied.
6. The risks: reported adverse events and the study's ability to detect uncommon or delayed ones.

Supplier documentation answers a different question from clinical evidence. A compound name or purity certificate does not establish equivalence to a trial formulation. The supplier evaluation checklist and research versus pharmaceutical grade guide explain the distinction.

Use the GLP-1 research hub to explore related compounds, or inspect semaglutide versus tirzepatide alongside the original publications. Each additional source should clarify a specific claim, its study setting, and its limits.